K2P18.1 translates T cell receptor signals into thymic regulatory T cell development

Ruck T.; Bock S.; Pfeuffer S.; Schroeter C.B.; Cengiz D.; Marciniak P.; Lindner M.; Herrmann A.; Liebmann M.; Kovac S.; Gola L.; Rolfes L.; Pawlitzki M.; Opel N.; Hahn T.; Dannlowski U.; Pap T.; Luessi F.; Schreiber J.A.; Wünsch B.; Kuhlmann T.; Seebohm G.; Tackenberg B.; Seja P.; Döring F.; Wischmeyer E.; Chasan A.I.; Roth J.; Klotz L.; Meyer zu Hörste G.; Wiendl H.; Marschall T.; Floess S.; Huehn J.; Budde T.; Bopp T.; Bittner S.; Meuth S.G.

Abstract

It remains largely unclear how thymocytes translate relative differences in T cell receptor (TCR) signal strength into distinct developmental programs that drive the cell fate decisions towards conventional (Tconv) or regulatory T cells (Treg). Following TCR activation, intracellular calcium (Ca2+) is the most important second messenger, for which the potassium channel K2P18.1 is a relevant regulator. Here, we identify K2P18.1 as a central translator of the TCR signal into the thymus-derived Treg (tTreg) selection process. TCR signal was coupled to NF-κB-mediated K2P18.1 upregulation in tTreg progenitors. K2P18.1 provided the driving force for sustained Ca2+ influx that facilitated NF-κB- and NFAT-dependent expression of FoxP3, the master transcription factor for Treg development and function. Loss of K2P18.1 ion-current function induced a mild lymphoproliferative phenotype in mice, with reduced Treg numbers that led to aggravated experimental autoimmune encephalomyelitis, while a gain-of-function mutation in K2P18.1 resulted in increased Treg numbers in mice. Our findings in human thymus, recent thymic emigrants and multiple sclerosis patients with a dominant-negative missense K2P18.1 variant that is associated with poor clinical outcomes indicate that K2P18.1 also plays a role in human Treg development. Pharmacological modulation of K2P18.1 specifically modulated Treg numbers in vitro and in vivo. Finally, we identified nitroxoline as a K2P18.1 activator that led to rapid and reversible Treg increase in patients with urinary tract infections. Conclusively, our findings reveal how K2P18.1 translates TCR signals into thymic T cell fate decisions and Treg development, and provide a basis for the therapeutic utilization of Treg in several human disorders.